Quarterly report · Q1

Period2023-04-01 → 2023-06-30
Filed2023-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥16.0bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥60.5bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥15.3bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥1.7bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥1.7bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥1.8bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.8bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥1.9bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥1.8bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥1.4bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.3bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥1.4bn2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥1.3bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥89.2bnat 2023-06-30Cons.Assets
Total assets¥87.1bnat 2023-03-31Cons.Assets
Total assets¥84.8bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥32.3bnat 2023-06-30Cons.Liabilities
Total liabilities¥32.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥56.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥54.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥50.5bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥15.2bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥14.5bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥50.512023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.082022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.942022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio63.8%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥55m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥42m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥13m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30−¥27m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥13m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥13m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥288m
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥1m
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥14.4bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥14.4bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥16.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥16.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥13m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥44m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥29m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥15m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥18m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥15m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥15m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥169m
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥124m
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥13.6bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥13.6bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥15m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥1.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 323
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)清陽監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)中市  俊也
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)槇田 憲一郎
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration15269000000JPY
Net sales (5-year summary)CurrentYTDDuration16023000000JPY
Net sales (5-year summary)Prior1YearDuration60461000000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration1805000000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration1809000000JPY
Ordinary income loss (5-year summary)Prior1YearDuration5232000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YTDDuration1323000000JPY
Profit loss attributable to owners of parent (5-year summary)CurrentYTDDuration1428000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration4238000000JPY
Comprehensive income (5-year summary)Prior1YTDDuration1792000000JPY
Comprehensive income (5-year summary)CurrentYTDDuration2563000000JPY
Comprehensive income (5-year summary)Prior1YearDuration5983000000JPY
Net assets (5-year summary)Prior1QuarterInstant50477000000JPY
Net assets (5-year summary)CurrentQuarterInstant56881000000JPY
Net assets (5-year summary)Prior1YearInstant54533000000JPY
Total assets (5-year summary)Prior1QuarterInstant84764000000JPY
Total assets (5-year summary)CurrentQuarterInstant89166000000JPY
Total assets (5-year summary)Prior1YearInstant87138000000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration46.94
Basic earnings loss per share (5-year summary)CurrentYTDDuration50.51
Basic earnings loss per share (5-year summary)Prior1YearDuration150.08
Diluted earnings per share (5-year summary)Prior1YTDDuration-
Diluted earnings per share (5-year summary)CurrentYTDDuration-
Diluted earnings per share (5-year summary)Prior1YearDuration-
Equity to asset ratio (5-year summary)Prior1QuarterInstant0.596
Equity to asset ratio (5-year summary)CurrentQuarterInstant0.638
Equity to asset ratio (5-year summary)Prior1YearInstant0.626
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember30563199
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember30563199
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant30563199
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant30563199
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember2269100
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember28272900
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember282729
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember21199
Number of shares issued shares voting rightsCurrentQuarterInstant30563199
Number of voting rights issued shares voting rightsCurrentQuarterInstant282729
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member2269100
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member2269100
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0742

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass